secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2022-12-07T23:59:59+00:00
Accession:  0000950170-22-026162
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya Therapeutics appoints Amy Burroughs to board; Eli Casdin resigns
-----------------------------------------------------------------------

- Eli Casdin resigned from board and audit committee effective Dec 5, 2022; no disagreement with company.
- Amy Burroughs appointed Class II director, term expiring at 2023 annual meeting.
- Burroughs receives annual cash retainer of $35,000 plus $7,500 for audit committee; granted option for 40,000 shares vesting monthly over 3 years.
- Burroughs is President & CEO of Cleave Therapeutics, brings >20 years healthcare/biotech experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000095017022026162/0000950170-22-026162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000095017022026162/tnya-20221205.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-026162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer